Barba, Maddalena, Yang, Li, Ph.D., Schünemann, Holger J., Sperati, Francesca, Grioni, Sara, Stranges, Saverio, Westerlind, Kim C., Blandino, Giovanni, Gallucci, M. (Michele), Lauria, Rossella, Malorni, Luca and Muti, Paola. (2009) Urinary estrogen metabolites and prostate cancer : a case-control study and meta-analysis. Journal of Experimental and Clinical Cancer Research, Vol.28 (Article 135). ISSN 1756-9966

PDF WRAP_Stranges_Urinary.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Available under License Creative Commons Attribution. Download (315Kb)

Abstract

Objective: To investigate prostate cancer (Pca) risk in relation to estrogen metabolism, expressed as urinary 2-hydroxyestrone (2-OHE1), 16α-hydroxyestrone (16α-OHE1) and 2-OHE1 to 16α-OHE1 ratio. Methods: We conducted a case-control study within the Western New York Health Cohort Study (WNYHCS) from 1996 to 2001. From January 2003 through September 2004, we completed the re-call and follow-up of 1092 cohort participants. Cases (n = 26) and controls (n = 110) were matched on age, race and recruitment period according to a 1:4 ratio. We used the unconditional logistic regression to compute crude and adjusted odds ratios (OR) and 95% confident interval (CI) of Pca in relation to 2-OHE1, 16αOHE1 and 2-OHE1 to 16α-OHE1 by tertiles of urine concentrations (stored in a biorepository for an average of 4 years). We identified age, race, education and body mass index as covariates. We also conducted a systematic review of the literature which revealed no additional studies, but we pooled the results from this study with those from a previously conducted case-control study using the DerSimonian-Laird random effects method. Results: We observed a non-significant risk reduction in the highest tertile of 2-OHE1 (OR 0.72, 95% CI 0.25-2.10). Conversely, the odds in the highest tertile of 16α-OHE1 showed a non-significant risk increase (OR 1.76 95% CI 0.62-4.98). There was a suggestion of reduced Pca risk for men in the highest tertile of 2-OHE1 to 16α-OHE1 ratio (OR 0.56, 95% CI 0.19-1.68). The pooled estimates confirmed the association between an increased Pca risk and higher urinary levels of 16α-OHE1 (third vs. first tertile: OR 1.82, 95% CI 1.09-3.05) and the protective effect of a higher 2-OHE 1 to 16α-OHE1 ratio (third vs. first tertile: OR 0.53, 95% CI 0.31-0.90). Conclusion: Our study and the pooled results provide evidence for a differential role of the estrogen hydroxylation pathway in Pca development and encourage further study.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) Q Science > QP Physiology
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Prostate -- Cancer -- Research, Cancer -- Endocrine aspects, Estrogen -- Physiological effect, Hydroxylation
Journal or Publication Title:	Journal of Experimental and Clinical Cancer Research
Publisher:	BioMed Central Ltd.
ISSN:	1756-9966
Date:	8 October 2009
Volume:	Vol.28
Number:	Article 135
Identification Number:	10.1186/1756-9966-28-135
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
References:	1. Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 2. Giovannucci E: Epidemiologic characteristics of prostate cancer. Cancer 1995:1766-77. 3. Bosland MC: The role of steroid hormones in prostate cancerogenesis. J Natl Cancer Inst Momogr 2000, 27:39-66. 4. Diamandis EP, Yu H: Does prostate cancer start at puberty? Clin Lab Anal 1996, 10(6):468-9. 5. Barba M, Terrenato I, Schünemann H, Fuhrman B, Sperati F, Teter B, Gallucci M, D'Amato A, Muti P: Indicators of Sexual and Somatic Development and Adolescent Body Size in Relation to Prostate Cancer Risk: Results from a Case-control Study. Urology 2008, 72(1):183-7. 6. Carruba: Estrogens and Mechanisms of Prostate Cancer Progression. Ann N Y Acad Sci 2006, 1089:201-7. 7. Bosland MC, Ford H, Horton LI: Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague- Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17β or diethylbestrol. Carcinogenesis 1995, 16:1311-7. 8. Ho SM, Lane K: Sex hormone-induction and dietary modulation of prostatic adenocarcinoma (PA) in animal models. Urol Oncol 1996, 2:110-5. 9. Ayala AG, Roj Y: Prostatic intraepithelial neoplasia: recent evidence. Arch Pathol Lab Med 2007, 131(8):1257-31. 10. Lotinum P, West K, Gibson KJ, Turner RT: Tissue-selective effects of continuous release of 2-hydrohyestrone and 16α-hydroxyestrone on bone, uterus and mammary gland in ovariectorized growing rats. J Endocrinol 2001, 170:165-174. 11. Suto A, Bradlow H, Wong GY, Osborne MP, Telang NT: Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat 1993, 27:193-202. 12. Telang NT, Suto A, Wong GY, Osborn MP, Bradlow HL: Induction by estrogen metabolite 16α-OHE1 of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992, 84:634-8. 13. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J, Schünemann H, Freudenheim JL, Hill H, Carruba G, Bradlow L: Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control 2002, 13(10):947-55. 14. Trevisan M, Dorne J, Falkner K, Russell M, Ram M, Muti P, Freudenheim JL, Nochajascki T, Hovay K: Drinking pattern and risk of non-fatal myocardial infarction: a population-based casecontrol study. Addiction 2004, 99:313-22. 15. Thompson IM, Ankerst D, Chi C, Lucia MS, Goodman PJ, Crowly JJ, Parnes HL, Coltman CA: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006, 98(8):529-34. 16. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH: Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998, 78(9):1250-5. 17. Andersson SO, Adami H, Bergström R, Wide L: Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study. Br J Cancer 1993, 1993(1):97-102. 18. Signorello LB, Tzonou A, Mantzoros CS, Lipworth L, Lagiou P, Hsieh C, Stampfer M, Trichopoulos D: Serum steroids in relation to prostate cancer risk in a case-control study (Greece). Cancer Causes Control 1997, 8(4):632-6. 19. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann HJ: Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 2008, 18(27):21. 20. Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Bdair F, Schünemann HJ: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 2008, 113(7):1685-94. 21. Akl EA, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P, Cook DJ, Schünemann HJ: Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 2008, 168(12):1261-9. 22. Capurso G, Schünemann H, Terrenato I, Moretti A, Koch M, Muti P, Capurso L, Delle Fave G: Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmaco Ther 2007, 26(8):1089-99. 23. Higgins JTS: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):11539-58. 24. Yang L, Gaikwad N, Meza J, Cavalieri EL, Muti P, Trock B, Rogan EG: Novel Biomarker for Risk of Prostate Cancer: results from a case-control study. Prostate 2009, 69(1):41-8. 25. Gann PH, Hennekens C, Ma J, Longcope C, Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996, 88(16):1118-26. 26. Hsing A: Hormones and prostate cancer: what's next? Epidemiol Rev 2001, 23(1):42-58. 27. Zhu BT, Coney A: Functional role of estrogen metabolism in target cells: reviews and perspectives. Carcinogenesis 1998, 19:1-27. 28. Lewis JS, Thomas T, Klinge CM, Gallo MA, Thomas T: Regulation of cell cycle and cyclins by16alpha-hydroxyestrone in MCF-7 breast cancer cells. J Mol Endocrinol 2001, 27:293-307. 29. Gupta M, McDougal A, Safe S: Estrogenic and antiestrogenic activities of alpha- and 2-hydroxyestrone of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol 1998, 67:413-9. 30. Bradlow HL, Sepkovic D, Telang NT, Osborne MP: Multifunctional aspects of the action of indol-3-carbinol as an antitumor agent. Ann NY Acad Sci 1999, 889:204-13. 31. Teas J, Cunningham J, Fowke JH, Nitcheva D, Kanwat CP, Boulware RJ, Sepkovic DW, Hurley TG, Herbert JR: Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina. Cancer Detect Prev 2005, 29(6):494-500. 32. Osborne MP, Bradlow H, Wong GYC, Telang NT: Upregulation of estradiol C16α-hydroxylation in human breast tissue: a potential biomarker of breast caner risk. J Natl Cancer Inst 1993, 85:1917-1920. 33. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC: A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. Environ Health Perspect 1997, 105(S3):601-5. 34. Kabat GC, Chang C, Sparano JA, Sepkovie DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL: Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997, 6(7):505-9. 35. Muti P, Bradlow H, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F: Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000, 11(6):635-40.
URI:	http://wrap.warwick.ac.uk/id/eprint/2653

Request changes to a record

Actions (login required)

View Item